SB203580

For research use only. Not for use in humans.

目录号：S1076 别名： RWJ 64809, PB 203580

SB203580 Chemical Structure

CAS No. 152121-47-6

SB203580 (RWJ 64809, PB 203580) 是一种p38 MAPK抑制剂，在THP-1细胞中IC50为0.3-0.5 μM，对SAPK3(106T)和SAPK4(106T)选择性低10倍，且阻断PKB磷酸化，IC50为3-5 μM。SB203580 可诱导线粒体自噬和细胞自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1565.11 现货
RMB 1195.54 现货
RMB 2193.43 现货
RMB 3864.74 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的SB203580发表文献627篇：

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述 SB203580 (RWJ 64809, PB 203580) 是一种p38 MAPK抑制剂，在THP-1细胞中IC50为0.3-0.5 μM，对SAPK3(106T)和SAPK4(106T)选择性低10倍，且阻断PKB磷酸化，IC50为3-5 μM。SB203580 可诱导线粒体自噬和细胞自噬。
特性 SB203580是第一个被报道的p38抑制剂。
靶点
p38 MAPK [1]
(THP-1 cells)		 PKB [1]
(THP-1 cells)
0.3 μM-0.5 μM 3 μM-5 μM
体外研究

SB203580作用于人类T细胞,鼠CT6 T细胞, 或BAF F7 B细胞，抑制IL-2诱导的增殖，IC50为3-5 μM。SB203580也抑制IL-2诱导的p70S6K激活, IC50 > 10 μM。SB203580也抑制PDK1活性，IC50为3-10 μM，这种抑制存在剂量依赖性。[1]SB203580抑制MAPKAPK2中p38-MAPK的刺激，IC50 为0.07 μM, 然而抑制完整SAPK/JNK活性时，IC50为3-10 μM。SB203580 高浓度时激活ERK通路,随后增强NF-κB转录活性。[2]SB203580作用于人类肝癌细胞(HCC)，诱导自体吞噬。[3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NH7WRopMcW6jc3WgRZN{[Xl? M2fI[FExKM7:TR?= MVqxOUBucW5? M2LoTmlvcGmkaYTzJJA{QCCPQWCgb4lv[XOnIIfpeIghUUN3MDDv[kAxNjZizszN NEfTd2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi95N{WwOVc4Lz55N{WwOVc4RC:jPh?=
THP-1 M4jjR2Z2dmO2aX;uJGF{e2G7 MlLFTY5pcWKrdIOgUHBUNWmwZIXj[YQhXE6IYXzwbIEheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yPiEQvF2= NGj2Omo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyOVc3QCd-MUizNlU4Pjh:L3G+
PBMC Mm\PSpVv[3Srb36gRZN{[Xl? M2T1d|E2KG2rbh?= NG\rZZNFVVOR M{nMNmlvcGmkaYTzJJRp\SC{ZXzlZZNmKG:oIHnueIVzdGW3a3nuMVEu[mW2YTD3bZRpKEmFNUCgc4YhOC5yM{eg{txO MoDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ|NkGzPVYoRjF{M{[xN|k3RC:jPh?=
SW1353 MULGeY5kfGmxbjDBd5NigQ>? NYD4VY9pOSCq NE\DfGdFVVOR MUfJcohq[mm2czDJUE03KHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvODVizszN NGPZdHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUG0NFc1OSd-MUGxOFA4PDF:L3G+
Hela MWfGeY5kfGmxbjDBd5NigQ>? Moi2SG1UVw>? NITmd4dKdmirYnn0d{BV[XRvaX7keYNm\CCKSW[xJGxVWiC2cnHud4FkfGm4YYTpc44hcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl{NkexNUc,OTh7Mk[3NVE9N2F-
PC12 MYLGeY5kfGmxbjDBd5NigQ>? MmruNVAh|ryP M3KwVmROW09? MVzBZ5RqfmG2ZYOgUpJnOi:DUlWgbY4hemG2IGDDNVIh[2WubIOgZZN{\XO|ZXSgZZMhUE9vMTDwdo91\WmwIHnu[JVkfGmxbh?= NX;0UpY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOFU3QDVpPkKxN|Q2Pjh3PD;hQi=>
RAW 264.7 MlrPR5l1d3SxeHnjJGF{e2G7 NWLubYJCOTJwNTFOwG0> Mn;ZNVJp NVzHTplxTE2VTx?= NYHoPWg6SmyxY3vzJIxmfGijbDD0c5hqdi2vZXTpZZRm\CCleYTveI95cWOrdIm= NHy2S|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S4OVUxPCd-MUe0PFU2ODR:L3G+
HCA2 Mo\LSpVv[3Srb36gRZN{[Xl? MUSyMlUh|ryP NVexc|QzUW6qaXLpeJMheDN6IH3l[IlifGWmIF3LNkBi[3SrdnH0bY9v MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7NkS3PFAoRjF5OU[0O|gxRC:jPh?=
U937 M1\hdGZ2dmO2aX;uJGF{e2G7 NX7BRnpnUW6qaXLpeJMhUkGNLX3l[IlifGWmIHnueIVz\mW{b36t[4FudWFxYX7pd49ugWOrbj3pcoR2[2WmIGP0ZZQyKHCqb4PwbI9zgWyjdHnvci=> MlXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThzNUexNlIoRjF6MUW3NVIzRC:jPh?=
U937 NXrYSFM1TnWwY4Tpc44hSXO|YYm= M{CyN2lvcGmkaYTzJGpCUy2vZXTpZZRm\CCrboTldoZmem:wLXfhcY1iN2GwaYPvcZlkcW5vaX7keYNm\CCyM{igdIhwe3Cqb4L5cIF1cW:w MmXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThzNUexNlIoRjF6MUW3NVIzRC:jPh?=
hESCs NHPt[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWx[|NQPSEQvF2= MlTPSG1UVw>? NWTwcZQzUW6mdXPld{Bk[XKmaX;tfY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cA>? NUPsbmNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFI{QTlpPkKzOlAzOzl7PD;hQi=>
RAW264.7 M{f2VGZ2dmO2aX;uJGF{e2G7 NHnGcVYyOCEQvF2= MUfJcoR2[2W|IHHueIlqdm[uYX3tZZRwenliYXP0bZZqfHliYomgbY5pcWKrdHnu[{BKVC1zzsKgdoVt\WG|ZR?= M2W4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{mxNFc5Lz5{M{e5NVA4QDxxYU6=
RAW264.7 MmL6SpVv[3Srb36gRZN{[Xl? Ml:1NVAh|ryP MnzFTY5lfWOnczDhcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHL5JIlvcGmkaYTpcochcU6RUzDy[Yxm[XOn MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MUC3PEc,OjN5OUGwO|g9N2F-
RAW264.7 MWrGeY5kfGmxbjDBd5NigQ>? MoLaNVAh|ryP NIrD[GRKdmS3Y3XzJIFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZpkhcW6qaXLpeIlv\yCQTzDy[Yxm[XOn NXKzPXc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVExPzhpPkKzO|kyODd6PD;hQi=>
RAW264.7 M4exOGZ2dmO2aX;uJGF{e2G7 NUT2TlBHOTBizszN NHLYeWFKdmirYnn0d{BNWFNvaX7keYNm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNkC1O{c,OjRyMU[wOVc9N2F-
IEC-18 Ml3WSpVv[3Srb36gRZN{[Xl? NXm3ZpRiOTBizszN MYnJcohq[mm2czDMVHMucW6mdXPl[EBxOzhiTVHQT{BxcG:|cHjvdplt[XSrb36= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd3OEGxNEc,OjN5NUixNVA9N2F-
Sf9 MkDlSpVv[3Srb36gZZN{[Xl? NVfjXnhDOzBibXnudy=> M1;3e2lvcGmkaYTpc44hd2ZiZoXscE1t\W6pdHigSmxCTy14SHnzMXRGXiC2YXfn[YQhcHWvYX6gVmlROiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDheZRweGixc4Doc5J6dGG2aX;uJJBz\S2rbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhcW6ldXLheIlwdiC5aYToJGFVWCCob4KgNkBpenNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEGg{txONg>? NX;yVHIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OVU3PTRpPkK2OFU2PjV2PD;hQi=>
sf21 NFH5NXhHfW6ldHnvckBie3OjeR?= M2jLUmJqdmSrbnegZYZncW6rdImgeI8hf2muZDD0fZBmKGi3bXHuJIJqd3SrbjDsZYJmdGynZDDwN|gh[WyyaHGgLFkhfG9iM{WyJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[yNUBqdnOnY4SgZ4VtdHNiU2DSJIFv[Wy7c3nzMEBM\CB;IECuNFIyPyEQvF2u MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh|NESzNUc,Ojh6M{S0N|E9N2F-
PBMC NHSzdJdHfW6ldHnvckBie3OjeR?= NYrX[GE1UW6qaXLpeIlwdiCxZjDUUmYu[WyyaHGgdJJw\HWldHnvckBjgSCuaYDvdI9tgXOjY3PoZZJq\GVvc4TpcZVt[XSnZDDoeY1idiCyZYLpdIhmemGuIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{NCCLQ{WwJF0hOC5yMkWg{txONg>? NXy4cYh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUi3N|c{OCd-OUi3N|c{ODxxYU6=
PBMC MYfGeY5kfGmxbjDhd5NigQ>? MlfSTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVUCuQRj3hcJBpeyCycn;keYN1cW:wIHL5JIh2dWGwIIDldolxcGW{YXygZoxwd2RibX;uc452[2ynYYKgZ4VtdHNiKGDCUWN{MSxiSVO1NEA:KDBwMEK1JO69VS5? NWPyNINWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
PBMC NE\3[45HfW6ldHnvckBie3OjeR?= NH;heXJKdmirYnn0bY9vKG:oIICzPEBOSVBia3nuZZNmKHKnbHH0[YQhXE6ILXHsdIhiKHKnbHXhd4Uh\nKxbTDw[ZJqeGincnHsJIJtd2:mIH3vco9vfWOuZXHyJINmdGy|IDjQRm1EMSxiSVO1NEA:KDBwMEO3JO69VS5? Mn7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJyNkG4O|YoRjF{ME[xPFc3RC:jPh?=
PBMC NH:4PGhHfW6ldHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIFnMNU1j\XSjIIDyc4R2[3Srb36gbY4hcHWvYX6gdIVzcXCqZYLhcEBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczjQRm1EeyluIFnDOVAhRSByLkC0PEDPxE1w NX7TRpFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
SW1353 MXTGeY5kfGmxbjDhd5NigQ>? MWnDc41xd3WwZDD3ZZMh\X[jbIXheIVlKG[xcjDpeJMh[WKrbHn0fUB1dyCrbnjpZol1KEmOLU[gdJJw\HWldHnvckBqdiCVV{GzOVMh[2WubIOgeJJm[XSnZDD3bZRpKGO7dH;rbY5meyCLTD2xJIFv\CCWTl[sJGlEPTBiPTCwMlA2KM7:TT6= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODl7OUS2O{c,OTB7OUm0Olc9N2F-
SW1353 M1jVeWZ2dmO2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKFSQRjDhcoQhUUxvMTDpcoR2[2WmIFnMMVYheHKxZIXjeIlwdiCrbjDoeY1idiClaH;u[JJwNXOjcnPvcYEhW1diMUO1N{Bk\WyuczygTWM2OCB;IECuNFUh|ryPLh?= MkHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUm0OlgoRjFyOUm5OFY5RC:jPh?=
THP1 M2DqeWZ2dmO2aX;uJIF{e2G7 MmnJTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBKVDFicILv[JVkfGmxbjDpckBpfW2jbjDUTHAyKGOnbHzzMEBKSzVyIE2gNE4xPSEQvF2u MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB5N{O2N{c,OThyN{ezOlM9N2F-
THP1 NGrQd5RHfW6ldHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hcW5iaIXtZY4hXEiSMTDj[YxteyxiSVO1NEA:KDBwMEWg{txONg>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB5N{O2N{c,OThyN{ezOlM9N2F-
THP1 M1K0XWZ2dmO2aX;uJIF{e2G7 NXW5fphoUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EB1fW2xcjDu[YNzd3OrczDmZYN1d3JvYXzwbIEhMFSQRj3hcJBp[SlicILv[JVkfGmxbjDpckBVUFBvMTDj[YxteyxiRVO1NEA:KDBwME[g{txONg>? NHO1R2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkC4OlQ5PSd-MUKwPFY1QDV:L3G+
THP1 NFfsdYNHfW6ldHnvckBie3OjeR?= NHTyPHZKdmirYnn0bY9vKG:oIIT1cY9zKG6nY4Lvd4l{KG[jY4TvdkBidHCqYTDy[Yxm[XOnIHL5JHRJWC1zIHPlcIx{NCCLQ{WwJF0hOC5yNzFOwG0v Mn\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4OVUoRjF3NkW4PFU2RC:jPh?=
monocytic cell Mn2xSpVv[3Srb36gZZN{[Xl? Moi1TY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JHRPTi2jbIDoZUBxem:mdXP0bY9vKHW|aX7nJIxqeG:yb3z5d4Fk[2ijcnnk[UB{fGmvdXzheIVlKGi3bXHuJI1wdm:leYTpZ{Bk\WyuczygTWM2OCB;IECuNFczKM7:TT6= NXjqSnNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK3Nlk3OzdpPkGyO|I6PjN5PD;hQi=>
THP1 NU\qR|J7TnWwY4Tpc44h[XO|YYm= M2fidmlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBNWFNvc4TpcZVt[XSnZDDUUmYu[WyyaHGgdJJw\HWldHnvckBqdiCqdX3hckBud26xY4n0bYMh[2WubIOgLHRJWC1zKTygTWM2OCB;IECuNFczKM7:TT6= MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzM{m3OFkoRjF3MUO5O|Q6RC:jPh?=
THP-1 NX21foQyTnWwY4Tpc44h[XO|YYm= M1nrZ2lvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBtcXCxcH;sfZNi[2OqYYLp[IUhe3SrbYXsZZRm\CCWTl[tZYxxcGFicILv[JVkfGmxbjDpckBVUFBvMTDj[YxteyBqaIXtZY4hdW:wb3P5eIlkKGOnbHzzLUwhUUN3MDC9JFAvODd{IN88UU4> M2O1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OEO3N|ExLz5zNUizO|MyODxxYU6=
THP1 MVvGeY5kfGmxbjDhd5NigQ>? MlftTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKGmwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlA4OiEQvF2u M33Sb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{WwN|Y4Lz5zNke1NFM3PzxxYU6=
PBMC MXfGeY5kfGmxbjDhd5NigQ>? MlTaTY5pcWKrdHnvckBw\iC|dHHwbJltd2OxY3PhcEBmdnSncn;0c5hqdiCEKGPFRkkhe3SrbYXsZZRm\CC2dX3vdkBv\WO{b4Ppd{Bn[WO2b4KgZYxxcGFiKGTOSk1idHCqYTmgdJJw\HWldHnvckBjgSCqdX3hckBx\XKrcHjldoFtKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzLHBDVUO|KTygTWM2OCB;IECuNVYh|ryPLh?= MoTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTd6NEC5N{c,QTd6NEC5N|ww[T5?
PBMC MYPGeY5kfGmxbjDhd5NigQ>? M13a[GNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDDsbZBweG:ueYPhZ4Np[XKrZHWgbY5lfWOnZDDUUmYu[WyyaHGgdoVt\WG|ZTD3ZZMh\GW2ZYLtbY5m\CCrbjDoeY1idiCyZYLpdIhmemGuIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{NCCLQ{WwJF0hOC5zOTFOwG0v Mn\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyN|EoRjF3NEW0NlMyRC:jPh?=
Sf9 Mof1SpVv[3Srb36gZZN{[Xl? M3vHVGlvcGmkaYTpc44hd2ZiZoXscE1t\W6pdHigSmxCTy14SHnzMXRGXiC2YXfn[YQhcHWvYX6gVmlROiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIJ6KG[udX;y[ZNk\W62IIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNkDPxE1w MkSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NUW2OVQoRjJ4NEW1OlU1RC:jPh?=
HEK293F M1rtbmZ2dmO2aX;uJIF{e2G7 NIrWT|lKdmirYnn0bY9vKG:oIIPv[Il2dSCjcoPlcoF1\SCjY4TpeoF1\WRiTj30[ZJucW6jbDDHV3QufGGpZ3XkJGJzfWerYTDtZYxigWliTWDLNUBmgHC{ZYPz[YQhcW5iSFXLNlk{TiClZXzsd{B2e2mwZzDGRW0ueDN6dHnk[UBieyC|dXLzeJJifGViYomgTW1CWCCjc4PhfUwhUUN3MDC9JFAvOjJizszNMi=> NETYdYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM3Oid-Mkm1OFE{PjJ:L3G+
HEK-293 Mo\sSpVv[3Srb36gZZN{[Xl? MXPJcohq[mm2aX;uJI9nKFKLUELLJIlvKE2GUD3zeIlufWyjdHXkJGhGUy1{OUOgZ4VtdHNib4\ldk1mgHC{ZYPzbY5oKE6RREKgZZN{\XO|ZXSgZZMhUUx6IIPlZ5JmfGmxbjygTWM2OCB;IECuNlUh|ryPLh?= NV64d41bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNFk5PjdpPkK3NVA6QDZ5PD;hQi=>
whole blood cell NVvnXHhjTnWwY4Tpc44h[XO|YYm= M1LrOVAvODFidH:gNVAxKHWP NGH0PJZKdmirYnn0bY9vKG:oIICzPE1z\WyjdHXkJGlNOS2kZYThJJJmdGWjc3WgZpkhf2ixbHWgZoxwd2RiY3XscJMh[XRiMUCg[U01KHSxIEGwJIUuQCCPLDDJR|UxKD1iMD6zOUDPxE1w NWOxXVRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4OVI4PTRpPkGyPFUzPzV2PD;hQi=>
PBMC MWTGeY5kfGmxbjDhd5NigQ>? NXTRZ5hlUW6qaXLpeIlwdiCxZjDwN|ghVUGSIHvpcoF{\SC{ZXzheIVlKFSQRj3hcJBp[SC{ZXzlZZNmKG[{b32gdIVzcXCqZYLhcEBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczCoVGJOSyluIFnDOVAhRSByLkW5JO69VS5? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjB4MUi3Okc,OTJyNkG4O|Y9N2F-
PBMC MnzLSpVv[3Srb36gZZN{[Xl? NYe0e4RxUW6qaXLpeIlwdiCxZjD0bIUhemWuZXHz[UBw\iC2dX3vdkBv\WO{b4Ppd{Bn[WO2b4KgZYxxcGFiZoLvcUBx\XKrcHjldoFtKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzMEBKSzVyIE2gNE42QSEQvF2u Mlj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ|NkGzPVYoRjF{M{[xN|k3RC:jPh?=
PBMC NITI[3hHfW6ldHnvckBie3OjeR?= MYTJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgWG5HNWGucHjhJJJmdGWjc3WgbY4hWEKPIHPlcIx{NCCLQ{WwJF0hOC53OTFOwG0v MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjh3Mke1OEc,OTJ6NUK3OVQ9N2F-
whole blood cell MliwSpVv[3Srb36gZZN{[Xl? MXSwMlAyKHSxIEGwNEB2VQ>? MV\Jcohq[mm2aX;uJI9nKHB|OD3y[YxifGWmIGTOSk1idHCqYTDy[Yxm[XOnIHL5JJdpd2ynIHLsc49lKGOnbHzzJIF1KDFyIHWtOEB1dyBzMDDlMVghVSxiSVO1NEA:KDBwOUSg{txONg>? MofiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ6NUK3OVQoRjF{OEWyO|U1RC:jPh?=
BMDC NEDvdoJCdnSraX7mcIFudWG2b4L5JIF{e2G7 M3m2b|EhcHJ? MlzZRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBEPTeETD:2JI1wfXOnIFLNSGMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBKVC14IIDyc4R2[3Srb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJJRwKEySUz3zeIlufWyjdHnvckBu\WG|dYLl[EBi\nSncjCxPEBpenNiYomgSWxKW0FuIFnDOVAhRSB|LkWg{txONg>? NFLUbJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0O|I2QSd-MkSwOFczPTl:L3G+
BMDC MXvBcpRqcW6obHHtcYF1d3K7IHHzd4F6 M16wdlEhcHJ? NESxW4JCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKEN3N1LMM|YhdW:3c3WgRm1FSyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKEmOLUGyJJA1OCCycn;keYN1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBxemmxcjD0c{BNWFNvc4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiMUigbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPSEQvF2u NFLtUoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0O|I2QSd-MkSwOFczPTl:L3G+
HEK-293 M1LK[WZ2dmO2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKFKLUELLJIlvKFCjbULDV2s1NXO2aX31cIF1\WRiSFXLMVI6OyClZXzsd{BwfmW{LXX4dJJme3OrbnegWGxTOiCjc4Pld5Nm\CCjczDJUFghe2WlcnX0bY9vNCCLQ{WwJF0hPi5|MTFOwG0v NYTZcFNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNFk5PjdpPkK3NVA6QDZ5PD;hQi=>
BMDC Mm[wRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? NV7vdHF7OSCqch?= MV7BcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJGM2P0KOL{[gcY92e2ViQl3ER{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHRPTmGucHjhJJBzd2S3Y4Tpc44heHKnaX7jeYJifGWmIH\vdkAyKGi{IIDybY9zKHSxIFzQV{1{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkAyQCCqcoOgZpkhTUyLU1GsJGlEPTBiPTC3MlUh|ryPLh?= MmHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEeyOVkoRjJ2MES3NlU6RC:jPh?=
macrophage-like cell M2C0O2FvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MlLSN|AhdWmwcx?= MXPBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIFjMMVYxKGSncnn2[YQhdWGlcn;wbIFo\S2uaXvlJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckB1emWjdHXkJFMxKG2rboOgZoVnd3KnIFzQV{B{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkAzPCCqcoOgZpkhTUyLU1GsJGlEPTBiPTC4MlYh|ryPLh?= NXfmb3I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVExQDlpPkKzPFEyODh7PD;hQi=>
WS MmjQSpVv[3Srb36gZZN{[Xl? NYm0THVDOi53IIXN MoK2TY5pcWKrdHnvckBw\iCjbnnzc416[2mwLXnu[JVk\WRiUEO4MYFteGijIHHjeIl3[XSrb36gbY4hcHWvYX6gbJVu[W5iVFXSWE1qdW2xcoThcIl{\WRiV2OgZ4VtdHNiYYPz[ZN{\WRiYYOgTHNROjdicHjvd5Bpd3K7bHH0bY9vKGG2IEKuOUB2VQ>? NUi5N2JuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2OVk5PzFpPkG3OlU6QDdzPD;hQi=>
WS NInsRolHfW6ldHnvckBie3OjeR?= M4HzZWlvcGmkaYTpc44hd2ZiTVuyJI1m\GmjdHXkJGhUWDJ5IIDoc5NxcG:{eXzheIlwdiCrbjDpcY1wenSjbHnz[YQhX1NiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGYu[WO2aX6gd5Rz\XO|IH\pZpJmew>? NIKwOIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m2OFc5OCd-MUe5OlQ4QDB:L3G+
WS MkntSpVv[3Srb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKHB|ODDt[YRq[XSnZDDNT|Ih[WO2aY\heIlwdiCrbjDXV{Bk\Wyucx?= NYLq[GNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OlQ4QDBpPkG3PVY1PzhyPD;hQi=>
A673 NGHHR5VyUFSVIHHzd4F6 NF7hN4VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 M1nrOpFJXFNiYYPzZZk> MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NHjFUlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NVjJVWJ4eUiWUzDhd5NigQ>? MlTydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NH3VN2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD NEn2eI9yUFSVIHHzd4F6 NYn5WIk6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| M3;6clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NIfxU21yUFSVIHHzd4F6 MkXpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| NUPzUIJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 MXfxTHRUKGG|c3H5 Mlf0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= M{C5T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 M{DQU5FJXFNiYYPzZZk> NVjlcFcyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MUTxTHRUKGG|c3H5 MonIdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= M16wOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
phospho-p38 / p38; 

PubMed: 25747578     


Mock-infected RD cells were treated with SB203580 at different concentrations (10, 25, 50 and 100μM) or 1.0% DMSO (negative control) and cell lysates were harvested for Western blotting at 6h post-treatment. β-actin was included as a loading control. 

p-ASK1 / ASK1 / P-JNK / p-MKK4 / p-ERK; 

PubMed: 24082073     


(B) AGS cells were infected with ASK1-HA-expressing adenoviruses for 24 h, pretreated with vehicle (DMSO) or 10 μM SB203580, and stimulated with or without H. pylori for 3 h. Immunoblots of the indicated proteins are shown. (C) AGS cells were transfected with NC or ASK1 siRNA for 48 h and treated with vehicle (DMSO) or 10 μM SB203580 for 4 h. Immunoblots of the indicated proteins are shown.

phospho-MK2(T334) / phospho-HSP27(S82) / phospho-Akt(T308) / phospho-Akt(S473); 

PubMed: 21737674     


Lysates from wild-type MEFs pretreated with or without SB203580 (10 μM, 30 min) and exposed to H2O2 (100 μM) for the indicated duration were analyzed by immunoblotting with the indicated antibodies.

25747578 24082073 21737674
Immunofluorescence
dsRNA / hnRNP A1; 

PubMed: 25747578     


RD cells were subjected to infection with EV71 and post-treated with SB203580 (p38 MAPK inhibitor) for 8h. SB203580-treated cells were fixed and the subcellular localisation of hnRNP A1 (red) was investigated by indirect immunofluorescence assay. Mock-infected and DMSO-treated cells were included as infection and solvent control, respectively. The images were taken at 100X magnification. Colocalisation quantification was based on the MOC using WCIF ImageJ software and represented as percent colocalisation at the respective drug concentrations. Error bars represent the standard deviation of duplicate data.

25747578
Growth inhibition assay
Cell viability ; 

PubMed: 23001390     


B16F10 cells were treated with a concentrations of SB203580 as indicated in figure a.

23001390
体内研究 SB203580作用于缺血性损伤，保护猪的心肌层。[4] SB203580有效保护携带系统性红斑狼疮的MRL/lpr鼠和治疗疾病。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
- 合并

细胞受体激酶磷酸化实验 :

4 μg羊PKBα抗体固定在25 μL蛋白G-亲和层析柱上过夜(或1.5 小时) ，用Buffer A (50 mM Tris, pH 为7.5, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na3VO4, 0.1% β-巯基乙醇，1% Triton X-100, 50 mM NaF, 5 mM焦磷酸钠, 0.1 mM苯甲磺酰氟, 1 μg/mL抑蛋白酶肽, 抑肽素, 亮抑酶肽,及1 μM微囊藻素)冲洗。固定的PKB抗体和0.5 ml细胞溶解物温育1.5小时，用含0.5 M NaCl的0.5 mL Buffer A冲洗三次, 再用0.5 mL Buffer B (含50 mM Tris-HCl, pH为7.5, 0.03% (w/v) Brij-35, 0.1 mM EGTA, 及 0.1% β-巯基乙醇)冲洗二次,最后用100 μL实验稀释buffer冲洗二次; 5×实验稀释buffer包含100 mM MOPS, pH为7.2, 125 mM β-甘油磷酸, 25 mM EGTA, 5 mM原钒酸钠, 及5 mM DTT。10 μL实验稀释buffer，40 μM蛋白激酶A抑制肽, 100 μM PKB-特定底物肽,及10 μCi [γ-32P]ATP，加到PKB酶免疫复合物中。反应在室温下震荡温育20分钟，40 μL反应物转移到其他试管中，加入20 μL 40%三氯乙酸，终止反应。在室温下混合，温育5分钟，40 μL转移到P81磷酸纤维素纸上，亲和处理30秒 。P81纸在0.75%磷酸中洗三次，然后在室温下加到丙酮中。 使用闪烁计数器测量γ-32P 渗透率。
细胞实验：

[1]
- 合并
  • Cell lines: CT6细胞, BA/F3 F7细胞
  • Concentrations: 0-30 μM
  • Incubation Time: 1小时
  • Method:

    CT6细胞和BA/F3 F7细胞在RPMI培养基中冲洗三次，然后培养在含5%胎牛血清，生长因子，抗生素，β-巯基乙醇的RPMI培养基中。2-5×106个CT6细胞悬浮在含5%胎牛血清的2 ml RPMI培养基上, 用SB203580预处理。然后加入20 ng/ml重组人类IL-2，在37 oC下刺激细胞5分钟，离心30秒，溶解于合适buffer中。稳定表达IL-2受体β链缺失突变的BA/F3细胞维持在含谷氨酸，5%胎牛血清和0.2 μg/mL G418的RPMI培养基中。大规模冲洗细胞，过夜处理，在用IL-2激活前再次冲洗。通过测定[3H]胸苷的渗透率，进行细胞增殖实验。


    (Only for Reference)
动物实验：

[5]
- 合并
  • Animal Models: 携带系统性红斑狼疮的雌性MRL/lpr鼠和雌性C57BL/6鼠
  • Dosages: 0.4mL/天
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 43 mg/mL (113.92 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
 5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 377.43
化学式

C21H16FN3OS
CAS号 152121-47-6
储存条件 粉状
溶于溶剂
别名 RWJ 64809, PB 203580

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2